QIAGEN N.V. (QGEN) furnishes U.S. GAAP quarterly report via Form 6-K

Rhea-AI Filing Summary

QIAGEN N.V. filed a Form 6-K as a foreign private issuer to provide its U.S. GAAP quarterly report for the three and six months ended June 30, 2025.

The quarterly report is furnished as Exhibit 99.1 and is incorporated by reference. The filing is signed on behalf of the company by Chief Financial Officer Roland Sackers.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________________

FORM 6-K

__________________________________

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2025

Commission File Number 001-38332

 __________________________________

QIAGEN N.V.

(Translation of registrant’s name into English)

 __________________________________

Hulsterweg 82

5912 PL Venlo

The Netherlands

(Address of principal executive office)

 __________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ý            Form 40-F  o

1

Table of Contents

QIAGEN N.V.

Form 6-K

TABLE OF CONTENTS

Item			Page
Other Information			3
Signatures			4
Exhibit Index			5

2

Table of Contents

OTHER INFORMATION

For the three and six months ended June 30, 2025, QIAGEN N.V. prepared its quarterly report under United States generally accepted accounting principles (U.S. GAAP). This quarterly report is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

3

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			QIAGEN N.V.
			By:			/s/ Roland Sackers
						Roland Sackers
						Chief Financial Officer

Date: August 21, 2025

4

Table of Contents

EXHIBIT INDEX

Exhibit No.						Exhibit
99.1						U.S. GAAP Quarterly Report for the Period Ended June 30, 2025

5

FAQ

What does QIAGEN N.V. (QGEN) report in this Form 6-K?

QIAGEN N.V. furnishes its U.S. GAAP quarterly report for the three and six months ended June 30, 2025. This report is attached as Exhibit 99.1 and is incorporated by reference into the Form 6-K filing.

Which accounting standards does QIAGEN N.V. (QGEN) use in this quarterly report?

The quarterly report for QIAGEN N.V. is prepared under United States generally accepted accounting principles (U.S. GAAP). The company specifies that the report covers the three and six months ended June 30, 2025 and is furnished as Exhibit 99.1.

Where can investors find the detailed QIAGEN N.V. (QGEN) quarterly financials?

Investors can find the detailed quarterly financial information in Exhibit 99.1, titled “U.S. GAAP Quarterly Report for the Period Ended June 30, 2025.” This exhibit is attached to and incorporated by reference in the Form 6-K.

Who signed the QIAGEN N.V. (QGEN) Form 6-K for the quarter ended June 30, 2025?

The Form 6-K is signed on behalf of QIAGEN N.V. by Roland Sackers, the company’s Chief Financial Officer. His electronic signature appears in the signatures section, confirming authorization for the filing under the Securities Exchange Act of 1934.

Is QIAGEN N.V. (QGEN) a foreign private issuer filing under Form 20-F or 40-F?

QIAGEN N.V. is a foreign private issuer that files or will file its annual reports under cover of Form 20-F, not Form 40-F. This status is indicated by the checked Form 20-F box in the Form 6-K filing.